Back to News
Market Impact: 0.2
Decoy Expands Pan-Filovirus Efforts Through FDA Pathway; Stock Up
Source: Nasdaq
Healthcare & BiotechTechnology & InnovationPrivate Markets & Venture
Decoy Therapeutics is exploring a pan-filovirus antiviral program targeting deadly pathogens including Ebola and Marburg, expanding the potential applications of its platform. The company is pursuing non-dilutive funding and public-health partnerships to support development, though the article provides no financial terms, clinical data, or commercialization timeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
DCOY0.45
More News
- Wall Street’s Nasdaq hits all-time high as AI frenzy gathers pace
- Data-Center Bet Makes ESDS One of India’s Best New Listings
- Asia stocks ride tech wave higher, oil stays subdued
- U.S. regulators rush to write crypto rulebook after Clarity Act stalls in Senate
- Meta is breaking out after introducing Muse AI agent. Where the stock is going, according to the charts
- Anthropic in talks to lease 1 gigawatt from Stream Data Centers- The Information